Telehealth availability and shipping for GLP-1 programs vary by state and by provider, but the federal rules apply everywhere. These state pages collect the regulatory caveats that apply nationwide, the licensing and pharmacy questions specific to your state, and an honest note on what we have and haven’t verified about provider availability there.
Federal FDA rules on compounded GLP-1 apply in every state: compounded semaglutide and tirzepatide are not FDA-approved, the shortages are resolved, and lawful 503A compounding is narrow. Your state’s pharmacy and telehealth rules add another layer, and provider availability is set by each provider — we mark it with a clear data-availability note and do not publish unverified availability as fact.
Each page gives the federal regulatory status as it applies in that state, the licensing caveat (the prescriber must be licensed for patients in your state), the pharmacy-fulfillment caveat (the dispensing pharmacy must hold a nonresident license there), a direct step to look up your state’s own boards, the questions to ask before enrolling, and a unique state FAQ.